Compare OXY & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXY | RMD |
|---|---|---|
| Founded | 1920 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 36.4B |
| IPO Year | N/A | 1995 |
| Metric | OXY | RMD |
|---|---|---|
| Price | $39.77 | $245.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 13 |
| Target Price | $49.73 | ★ $289.09 |
| AVG Volume (30 Days) | ★ 8.5M | 924.4K |
| Earning Date | 11-10-2025 | 01-29-2026 |
| Dividend Yield | ★ 2.41% | 0.98% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | 1.39 | ★ 9.77 |
| Revenue | ★ $26,601,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | N/A | $9.85 |
| Revenue Next Year | N/A | $7.36 |
| P/E Ratio | $28.66 | ★ $25.05 |
| Revenue Growth | N/A | ★ 9.36 |
| 52 Week Low | $34.79 | $199.92 |
| 52 Week High | $53.20 | $293.81 |
| Indicator | OXY | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 43.12 |
| Support Level | $39.72 | $241.66 |
| Resistance Level | $40.47 | $247.45 |
| Average True Range (ATR) | 0.82 | 4.94 |
| MACD | -0.09 | -0.28 |
| Stochastic Oscillator | 29.91 | 18.66 |
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,327 thousand barrels of oil equivalent per day in 2024 at a ratio of roughly 52% oil and natural gas liquids and 48% natural gas.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.